Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

February 21, 2024

https://www.globenewswire.com/news-release/2024/02/21/2832730/0/en/Mainz-Biomed-Establishes-Strategic-Partnership-with-TomaLab-to-Expand-Availability-of-ColoAlert-in-Italy.html

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership signifies a major step forward in enhancing colorectal cancer screening and diagnostics within the Italian healthcare system as it enables the implementation of ColoAlert® into Italy’s robust healthcare framework, providing patients with access to a cutting-edge diagnostic solution that combines convenience with clinical excellence.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.